

CADTH RAPID RESPONSE REPORT:
SUMMARY WITH CRITICAL APPRAISAL

Frequency of Complete Blood Counts for Patients at Risk of Heparin-Induced Thrombocytopenia: A Review of Guidelines

Service Line: Rapid Response Service
Version: 1.0
Publication Date: October 2, 2018
Report Length: 7 Pages

Authors: Veronica Poitras, PhD; Lorna Adcock

Cite As: Frequency of complete blood counts for patients at risk of heparin-induced thrombocytopenia: a review of guidelines. Ottawa: CADTH; 2018 Oct. (CADTH rapid response report: summary with critical appraisal).

ISSN: 1922-8147 (online)

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Abbreviations

HIT Heparin-induced thrombocytopenia

Context and Policy Issues

Cardiac patients, such as those with myocardial infarction or unstable angina, are routinely given antithrombotic therapy (i.e., the combination of anticoagulant and antiplatelet therapy) to prevent the formation or extension of blood clots.¹ Heparins, including unfractionated heparin and low-molecular weight heparin, are one class of anticoagulants that act by indirectly inhibiting thrombin, an enzyme that catalyzes coagulation-related reactions.¹ While effective in reducing morbidity and mortality associated with thrombotic conditions,² exposure to heparin may result in an adverse immune-mediated reaction termed heparin-induced thrombocytopenia (HIT).³ As the name suggests, HIT is a reduction in platelets (thrombocytopenia; defined as a platelet [thrombocyte] count $<150 \times 10^9/L$) that follows heparin exposure.⁴

There are two types of HIT; type 1 (HIT-I) is mild, transient and not clinically significant, whereas type 2 (HIT-II) is a clinically significant IgG antibody-mediated process in which platelet activation occurs, leading to a hypercoagulant state.² In general medical practice, the term “HIT” is used to refer to HIT-II specifically.² Although a reduction in platelets typically increases the risk of bleeding, in patients with HIT there is a paradoxical hypercoagulation due to an increase in platelet activation and thrombin generation.³ HIT can result in venous or arterial thrombosis, leading to serious morbidity (e.g., heart attack or stroke, end-organ damage, limb gangrene) in up to 30% of patients, or mortality in 5 to 10% of patients.^{2,3} Approximately 50% of patients who undergo cardiac surgery develop HIT antibodies, but only 1 to 2% develop clinical HIT (thrombocytopenia, with or without thrombosis).⁴

Screening for HIT usually involves serial monitoring of platelet levels in patients who are receiving heparin.⁵ However, it has been suggested that this serial monitoring also has the potential to cause harm, due to resultant unnecessary withdrawal of heparin and replacement by non-heparin anticoagulants in patients without HIT.⁵ In 2012, the American College of Chest Physicians published guidelines suggesting that platelet count be monitored every 2 or 3 days from day 4 to day 14 (or until heparin is stopped) for patients receiving heparin who are considered to have more than a 1% risk of HIT, and that platelet count not be monitored for patients who are considered to have less than a $<1\%$ risk.⁴ However, these were weak recommendations made on evidence that was rated as being “very low” or “low” in quality, and there was a difference of opinion among the experts involved in guideline development.⁶

The purpose of this report is to examine recent evidence-based guidelines regarding the use of complete blood counts to monitor for HIT in cardiac patients receiving intravenous unfractionated heparin.

Research Question

What are the evidence-based guidelines regarding the frequency of complete blood counts to monitor for heparin-induced thrombocytopenia during intravenous heparin infusions for cardiac conditions?

Key Findings

No relevant evidence-based guidelines were identified regarding the frequency of complete blood counts to monitor for heparin-induced thrombocytopenia during intravenous heparin infusions for cardiac conditions.

Methods

Literature Search Methods

A limited literature search was conducted on key resources including Ovid Medline, PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases and a focused Internet search. No methodological filters were applied to limit retrieval by publication type. The search was limited to English language documents published between January 1, 2013 and September 6, 2018.

Selection Criteria and Methods

One reviewer screened citations and selected studies. In the first level of screening, titles and abstracts were reviewed and potentially relevant articles were retrieved and assessed for inclusion. The final selection of articles was based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Population	Cardiac patients receiving intravenous unfractionated heparin (i.e., ST elevated myocardial infarction, non-ST elevated myocardial infarction, unstable angina)
Intervention	Complete blood counts to monitor for heparin induced thrombocytopenia
Comparator	No comparator
Outcomes	Evidence-based guidelines
Study Designs	Guidelines

Exclusion Criteria

Articles were not eligible for inclusion if they did not meet the selection criteria outlined in Table 1, they were duplicate publications, were published prior to 2013, or were guidelines with unclear methodology.

Summary of Evidence

Quantity of Research Available

A total of 218 citations were identified in the literature search. Following screening of titles and abstracts, all 218 citations were excluded; no publications met the inclusion criteria for this report. Appendix 1 presents the PRISMA⁷ flowchart of the study selection.

Summary of Findings

No relevant evidence-based guidelines were identified regarding the frequency of complete blood counts to monitor for heparin-induced thrombocytopenia during intravenous heparin infusions for cardiac conditions; therefore, no summary can be provided.

Limitations

No relevant evidence-based guidelines were identified. It is possible that evidence-based guidelines exist that were published more than 5 years ago and were excluded by the current date-limited search (e.g., including the 2012 American College of Chest Physicians guidelines⁴ mentioned previously). However, given that the 2012 guidelines identified insufficient evidence,⁶ older guidelines would likely be outdated.

Conclusions and Implications for Decision or Policy Making

No relevant evidence-based guidelines were identified regarding the frequency of complete blood counts to monitor for HIT during intravenous heparin infusions for cardiac conditions. Evidence-based guidance is needed to inform when platelet levels should be monitored, and at what frequency, to monitor for HIT in cardiac patients who are receiving intravenous heparin.

References

1. Lincoff A. Anticoagulant therapy in acute ST elevation myocardial infarction. In: Post T, ed. *UpToDate*. Waltham (MD): UpToDate; 2018: www.uptodate.com. Accessed 2018 Oct 2.
2. Fathi M. Heparin-induced thrombocytopenia (HIT): identification and treatment pathways. *Glob Cardiol Sci Pract*. 2018;2018(2):15.
3. Prince M, Wenham T. Heparin-induced thrombocytopenia. *Postgrad Med J*. 2018;94(1114):453-457.
4. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e495S-e530S.
5. Linkins LA. Heparin induced thrombocytopenia. *BMJ*. 2015;350:g7566.
6. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):53S-70S.
7. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol*. 2009;62(10):e1-e34.

Appendix 1: Selection of Included Studies

